

3 February 2020

ASX ANNOUNCEMENT

ADMEDUS ANNOUNCES FINALISATION OF LICENSE AND ASSOCIATED MILESTONE PAYMENT WITH 4C MEDICAL

MINNEAPOLIS, MN – Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) announces the complete transfer of its unique Sterilisation Method as part of its ADAPT[®] tissue treatment process to 4C Medical Technologies, Inc. (4C Medical).

4C Medical is a Minnesota-based developer of AltaValve[™], a minimally invasive device for mitral valve repair. The technology transfer follows 4C Medical validating the process.

As per the Admedus supply agreement with 4C Medical, 4C Medical will pay an additional \$US1 Million (\$US 0.44M previously received) to use the technology to sterilise the ADAPT[®] tissue incorporated in its transcatheter mitral valve replacement (TMVR) AltaValve[™] system device.

The 4C Medical implant utilises tissue processed by Admedus' clinically superior ADAPT[®] Tissue Engineering Process for the functioning leaflet component of its valve. It will benefit from this technology to optimise function and durability.¹

“For the millions of patients suffering from Mitral Regurgitation, Admedus is proud to provide the transformative healing advantages of ADAPT[®] treated tissue with demonstrated clinically superior performance over ten years.” Admedus Chief Executive Officer, Mr Wayne Paterson said.

¹ *The 4C Medical design is the first Mitral Regurgitation (MR) therapy that preserves the native mitral valve and left ventricle. It is a stent-like structure shaped in the form of a ball and it can be delivered in a collapsed position and, once deployed, it springs back into the ball shape. In the middle of the ball is a short small 'chimney' where the artificial heart valve (containing the Admedus-supplied tissue) is placed. This artificial valve is placed above the native valve that is still working to some degree, preventing MR. The design eliminates the known problems of current TMVR technologies.*

ENDS

Admedus Limited


Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com



About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications

E: WE-AUAdmedus@we-worldwide.com

P: +61 401 018 828

www.admedus.com

Twitter: [@Admedus](https://twitter.com/Admedus)

Facebook: www.facebook.com/pages/Admedus